Long-term Treatment of Steroid-dependent Myasthenia Gravis Patients with Low-dose Tacrolimus
スポンサーリンク
概要
- 論文の詳細を見る
Objective To examine the long-term effects of tacrolimus in steroid-dependent myasthenia gravis (MG) patients. Patients and Methods We administered tacrolimus at 3 mg/day to 10 generalized MG patients presented with clinical worsening by a reduction in dose of prednisolone. The effects of tacrolimus were assessed by using the MG activities of daily living (MG-ADL) profile and the post-intervention status criteria provided by the Myasthenia Gravis Foundation of America (PSC-MGFA). Results Seven patients were able to use tacrolimus without serious adverse effects for 1.0-5.1 years (mean 3.1 years). Further, its administration improved myasthenic symptoms to the level of pharmacologic remission or minimal manifestations of PSC-MGFA in 5 patients and made it possible to discontinue prednisolone administration in 4 of those 5. However, despite improvements caused by tacrolimus, the reduction in dose of prednisolone caused worsening of symptoms in another 2 patients. In addition, blood trough levels of tacrolimus lower than the recommended range were effective to maintain long-term improvements in 2 patients. Conclusions Administration of tacrolimus induced long-term improvements and enabled replacement of prednisolone in patients with intractable steroid-dependent MG.
- 社団法人 日本内科学会の論文
著者
-
Kuroda Yasuo
佐賀大学 医学部内科
-
Nagaishi Akiko
Division of Neurology, Department of Internal Medicine, Saga University Faculty of Medicine
-
Yukitake Motohiro
Division of Neurology, Department of Internal Medicine, Saga University Faculty of Medicine
-
Kuroda Yasuo
Division of Neurology, Department of Internal Medicine, Saga University Faculty of Medicine
関連論文
- Long-term Treatment of Steroid-dependent Myasthenia Gravis Patients with Low-dose Tacrolimus
- Incidence and Clinical Significances of Human T-cell Lymphotropic Virus Type I-Associated Myelopathy with T2 Hyperintensity on Spinal Magnetic Resonance Images
- A Hyperdense Artery Sign and Middle Cerebral Artery Dissection
- The constitutive and inducible expression of Nurr1, a key regulator of dopaminergic neuronal differentiation, in human neural and non-neural cell lines
- Amyloid precursor protein β-secretase(BACE) mRNA expression in human neural cell lines following induction of neuronal differentiation and exposure to cytokines and growth factors
- Nicastrin, a key regulator of presenilin function, is expressed constitutively in human neural cell lines
- Cytokine-regulated expression of prion protein (PrP) gene in human neural cell lines
- Retinoic acid-induced neuronal differentiation regulates expression of mRNAs for neurotrophins and neurotrophin receptors in a human embryonal carcinoma cell line NTera2
- Necrotizing Myopathy in a Patient with Chronic Hepatitis C Virus Infection : a Case Peport and a Review of the Literature
- β-Catenin expression in human neural cell lines following exposure to cytokines and growth factors